Lung cancer is the second most common cancer in both men and women – according to the American Cancer Society, in the United States alone about 234,000 new case of lung cancer will be diagnosed in 2018. About 154,000 Americans will die from lung cancer in 2018, making it the leading cause of cancer death among both men and women.
G1 is currently studying trilaciclib for the treatment of SCLC and lerociclib for the treatment of EGFRm NSCLC.
Three randomized Phase 2 trials of trilaciclib have shown multi-lineage myelopreservation benefits in SCLC patients. In a trial in first-line SCLC, trilaciclib was administered in combination with a chemotherapy regimen of etoposide and carboplatin (NCT02499770); topline data were released in March and additional data were reported at the European Society of Medical Oncology 2018 Congress. In another first-line SCLC trial, trilaciclib was administered in combination with the same chemotherapy regimen and the checkpoint inhibitor Tecentriq® (atezolizumab) (NCT03041311); topline data were reported in November 2018. The company issued a press release on positive topline data from a trial in combination with chemotherapy in previously treated SCLC (NCT02514447) on December 19, 2018.
There are currently no trilaciclib clinical trials enrolling new participants.
Click here for trilaciclib data publications and presentations.